ロード中...
Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma
Histone deacetylase 6 (HDAC6) is an attractive target for cancer therapeutic intervention. Selective HDAC6 inhibitors is important to minimise the side effects of pan inhibition. Thus, new class of hydroxamic acid-based derivatives were designed on structural basis to perform preferential activity a...
保存先:
| 出版年: | J Enzyme Inhib Med Chem |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6522981/ https://ncbi.nlm.nih.gov/pubmed/31072216 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14756366.2019.1613987 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|